Avenue Therapeutics Inc.(ATXI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATXI Avenue Therapeutics Inc.

Post-Market Trading 11-05 16:12:28 EST

2.20

+0.00

0.00%

High2.33	Low2.20	Vol27.09K
Open2.24	D1 Closing2.20	Amplitude5.91%
Mkt Cap3.15M	Tradable Cap2.83M	Total Shares1.43M
T/O61.28K	T/O Rate2.11%	Tradable Shares1.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ATXI","market":"US","secType":"STK","nameCN":"Avenue Therapeutics Inc.","latestPrice":2.2,"timestamp":1730840399994,"preClose":2.2,"halted":0,"volume":27087,"delay":0,"floatShares":1286395,"shares":1431356,"eps":-28.402174,"marketStatus":"Post-Market Trading","change":0,"latestTime":"11-05 16:12:28 EST","open":2.24,"high":2.33,"low":2.2,"amount":61276.31162190001,"amplitude":0.059091,"askPrice":2.5,"askSize":500,"bidPrice":2.17,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-28.402174,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1730854800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1497585600000,"exchange":"NASDAQ","adjPreClose":2.2,"preHourTrading":{"tag":"盘前","latestPrice":2.37,"preClose":2.2,"latestTime":"09:25 EST","volume":1451,"amount":3411.5698703000003,"timestamp":1730816727020},"volumeRatio":0.443225},"requestUrl":"/m/hq/s/ATXI/tweets","defaultTab":"tweets","newsList":[{"id":"2467777686","title":"Allarity Therapeutics Names Alexander Epshinsky CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2467777686","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467777686?lang=en_us&edition=fundamental","pubTime":"2024-09-13 23:32","pubTimestamp":1726241546,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics (ALLR) said Friday it appointed Alexander Epshinsky as chief financial officer, succeeding Joan Brown.The company said Epshinsky previously served as controller at Avenue Therapeutics (ATXI).","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATXI","LENZ","ALLR"],"gpt_icon":0},{"id":"2467777631","title":"Allarity Therapeutics Names Alexander Epshinsky CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2467777631","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467777631?lang=en_us&edition=fundamental","pubTime":"2024-09-13 23:32","pubTimestamp":1726241546,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["ALLR","BK4007","BK4139","ALLR.AU","ATXI"],"gpt_icon":0},{"id":"2467720879","title":"Allarity Therapeutics Names Alex Epshinsky Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2467720879","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467720879?lang=en_us&edition=fundamental","pubTime":"2024-09-13 21:04","pubTimestamp":1726232640,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics has Alex Epshinsky as its new finance chief.The Boston clinical-stage pharmaceutical company said Epshinsky most recently served as controller at Avenue Therapeutics.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ALLR","ATXI"],"gpt_icon":0},{"id":"2459134945","title":"Fortress Biotech Inc - Qtrly  Shr Loss $0.73","url":"https://stock-news.laohu8.com/highlight/detail?id=2459134945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459134945?lang=en_us&edition=fundamental","pubTime":"2024-08-14 04:05","pubTimestamp":1723579546,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA3B71G6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DERM","CKPT","ATXI","BK4139","BK4007","FBIO"],"gpt_icon":0},{"id":"2459134929","title":"Fortress Biotech Inc - FDA Accepted Bla Resubmission for Cosibelimab to Treat Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2459134929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459134929?lang=en_us&edition=fundamental","pubTime":"2024-08-14 04:05","pubTimestamp":1723579546,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA3B71G6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DERM","BK4157","FBIO","IE00B66KJ199.SGD","AEIS","BK6522","CKPT","BK4139","BK6088","IE00B19Z4B17.USD","IE0031619046.USD","BLZ.SI","ATXI","BK4007","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2459134134","title":"Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2459134134","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459134134?lang=en_us&edition=fundamental","pubTime":"2024-08-14 04:05","pubTimestamp":1723579500,"startTime":"0","endTime":"0","summary":"PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults. FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024. MIAMI, Aug. 13, 2024  -- Fortress Biotech, Inc.  , an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2024.In March 2024, the FDA accepted the NDA for DFD-29  and set a PDUFA goal date of November 4, 2024.If approved, DFD-29 has the potential to be the new treatment paradigm for the millions of patients suffering from inflammatory lesions and erythema of rosacea. Both double blinded, randomized controlled DFD-29 Phase 3 clinical tria","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AEcy1bQEW49pdl430uN.3Q--~B/aD0zNDY7dz00NTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b3f034180af5ad6bdba856b546d8c273","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AEcy1bQEW49pdl430uN.3Q--~B/aD0zNDY7dz00NTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b3f034180af5ad6bdba856b546d8c273"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fortress-biotech-reports-second-quarter-200500951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IGA","ATXI","DERM","CKPT","BK4139","FBIOP","FBIO"],"gpt_icon":0},{"id":"2458546971","title":"Avenue Therapeutics Q2 EPS $(6.43) Misses $(1.05) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2458546971","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458546971?lang=en_us&edition=fundamental","pubTime":"2024-08-10 04:10","pubTimestamp":1723234249,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(6.43) per share which missed the analyst consensus estimate of $(1.05) by 512.38 percent. This is a 83.4 percent increase over losses of $(38.74) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40295038/avenue-therapeutics-q2-eps-6-43-misses-1-05-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ATXI"],"gpt_icon":0},{"id":"2457304402","title":"Avenue Therapeutics Inc    expected to post a loss of $1.05 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2457304402","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457304402?lang=en_us&edition=fundamental","pubTime":"2024-08-06 20:56","pubTimestamp":1722948968,"startTime":"0","endTime":"0","summary":"* Avenue Therapeutics Inc     is expected to report results on August 8 (estimated) for the period ending June 30 2024   *    * LSEG's mean analyst estimate for Avenue Therapeutics Inc is for a loss o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATXI","LENZ"],"gpt_icon":0},{"id":"2446496463","title":"Avenue Therapeutics Stockholders Approve Key Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2446496463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446496463?lang=en_us&edition=fundamental","pubTime":"2024-06-27 05:17","pubTimestamp":1719436661,"startTime":"0","endTime":"0","summary":"The latest update is out from Avenue Therapeutics (ATXI). At the 2024 Annual Meeting of a company conducted virtually, stockholders approved three ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/avenue-therapeutics-stockholders-approve-key-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/avenue-therapeutics-stockholders-approve-key-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATXI","BK4007","LENZ"],"gpt_icon":0},{"id":"2441098955","title":"Avenue Therapeutics (ATXI) Gets a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2441098955","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441098955?lang=en_us&edition=fundamental","pubTime":"2024-06-07 23:45","pubTimestamp":1717775125,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Avenue Therapeutics (ATXI – Research Report). The compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/avenue-therapeutics-atxi-gets-a-buy-from-maxim-group?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/avenue-therapeutics-atxi-gets-a-buy-from-maxim-group?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATXI","BK4007"],"gpt_icon":0},{"id":"2441087924","title":"U.S. RESEARCH ROUNDUP-Ciena, Huntsman, Prog Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2441087924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441087924?lang=en_us&edition=fundamental","pubTime":"2024-06-07 14:53","pubTimestamp":1717743239,"startTime":"0","endTime":"0","summary":"June 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ciena, Huntsman and Prog Holdings, on Friday.    HIGHLIGHTS      ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAN","BK4104","CPB","FTAI","MCRB","MSFT","MTN","ATXI","EMR","COLL","CIEN","LU1989772923.USD","BK4532","LU0320765646.SGD","LU1989772840.SGD","IE00BFSS8Q28.SGD","SYF","LU2023250843.SGD","TRGP","LU0061475181.USD","DOCU","BK4166","LU0106831901.USD","CRMT","BK4227","AFRM","LYFT","BK4549","UPST","IE0009356076.USD","IE00B7KXQ091.USD","COF","LU0061474960.USD","LU0082616367.USD","DFS","BK4539","MRNA","PRG","RLAY","VSCO","LRCX","PVH","SJM","LZ","BK4106","HUN","LPRO","SOFI","BRZE","LU0348723411.USD"],"gpt_icon":0},{"id":"2441088751","title":"Avenue Therapeutics Inc : Maxim Group Cuts Target Price to $12 From $56.25 to Reflect 1-for-75 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2441088751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441088751?lang=en_us&edition=fundamental","pubTime":"2024-06-07 12:12","pubTimestamp":1717733533,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics Inc : Maxim Group Cuts Target Price to $12 From $56.25 to Reflect 1-for-75 Reverse Stock Split","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240607:nFWN3I418A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LENZ","ATXI","BK4007"],"gpt_icon":0},{"id":"2437515847","title":"BRIEF-Avenue Therapeutics  Received Notice From Nasdaq Notifying Co Is In Compliance With All Requirement Set Forth In Nasdaq Listing Rule 5550(B)(1)","url":"https://stock-news.laohu8.com/highlight/detail?id=2437515847","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2437515847?lang=en_us&edition=fundamental","pubTime":"2024-05-23 20:54","pubTimestamp":1716468871,"startTime":"0","endTime":"0","summary":"May 23 (Reuters) - Avenue Therapeutics Inc   :   * AVENUE THERAPEUTICS:  RECEIVED NOTICE FROM NASDAQ NOTIFYING CO IS IN COMPLIANCE WITH ALL REQUIREMENT SET FORTH IN NASDAQ LISTING RULE 5550(B)(1)Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD",".IXIC","BK4112","NDAQ","QQQ","SQQQ","BK4588","LENZ","LU2095319765.USD","NQmain","MNQmain","B","BK4585","TQQQ","BK4139","BK4161","PSQ","BK4007","ATXI","QID","LU2210149790.SGD","QLD"],"gpt_icon":0},{"id":"2435637981","title":"Avenue Therapeutics Q1 EPS $(15.40) Misses $(9.00) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2435637981","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435637981?lang=en_us&edition=fundamental","pubTime":"2024-05-15 20:49","pubTimestamp":1715777348,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(15.40) per share which missed the analyst consensus estimate of $(9.00) by 71.11 percent. This is a 85.01 percent increase over losses of $(102.75) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38843129/avenue-therapeutics-q1-eps-15-40-misses-9-00-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATXI","LENZ"],"gpt_icon":0},{"id":"2435329616","title":"Avenue Therapeutics 1Q Loss/Shr $15.40 >ATXI","url":"https://stock-news.laohu8.com/highlight/detail?id=2435329616","media":"DowjonesLive","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435329616?lang=en_us&edition=fundamental","pubTime":"2024-05-15 20:31","pubTimestamp":1715776260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"dowjones_live","symbols":["BK4007","ATXI"],"gpt_icon":0},{"id":"2434917318","title":"BRIEF-Avenue Therapeutics May Offer Shares Of Common Stock Having Offering Price Of Up To $3.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2434917318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2434917318?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:55","pubTimestamp":1715374556,"startTime":"0","endTime":"0","summary":"May 10 (Reuters) - Avenue Therapeutics Inc   :   * AVENUE THERAPEUTICS INC: MAY OFFER SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $3.9 MILLION FROM TIME TO TIME THROUGH AGENTSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATXI","BK4139","LENZ","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avenuetx.com","stockEarnings":[{"period":"1week","weight":-0.127},{"period":"1month","weight":0.0602},{"period":"3month","weight":-0.12},{"period":"6month","weight":-0.5},{"period":"1year","weight":-0.8828},{"period":"ytd","weight":-0.8178}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.014023},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.105438},{"month":3,"riseRate":0.571429,"avgChangeRate":0.067877},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.168509},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.016327},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.057418},{"month":7,"riseRate":0.125,"avgChangeRate":-0.101087},{"month":8,"riseRate":0.375,"avgChangeRate":-0.057572},{"month":9,"riseRate":0.125,"avgChangeRate":0.144298},{"month":10,"riseRate":0.25,"avgChangeRate":-0.242638},{"month":11,"riseRate":0.375,"avgChangeRate":-0.045121},{"month":12,"riseRate":0.428571,"avgChangeRate":0.079717}],"exchange":"NASDAQ","name":"Avenue Therapeutics Inc.","nameEN":"Avenue Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avenue Therapeutics Inc.(ATXI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avenue Therapeutics Inc.(ATXI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avenue Therapeutics Inc.,ATXI,Avenue Therapeutics Inc.股票,Avenue Therapeutics Inc.股票老虎,Avenue Therapeutics Inc.股票老虎国际,Avenue Therapeutics Inc.行情,Avenue Therapeutics Inc.股票行情,Avenue Therapeutics Inc.股价,Avenue Therapeutics Inc.股市,Avenue Therapeutics Inc.股票价格,Avenue Therapeutics Inc.股票交易,Avenue Therapeutics Inc.股票购买,Avenue Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avenue Therapeutics Inc.(ATXI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avenue Therapeutics Inc.(ATXI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}